IL301350A - Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) - Google Patents
Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)Info
- Publication number
- IL301350A IL301350A IL301350A IL30135023A IL301350A IL 301350 A IL301350 A IL 301350A IL 301350 A IL301350 A IL 301350A IL 30135023 A IL30135023 A IL 30135023A IL 301350 A IL301350 A IL 301350A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- once
- day
- antibody
- week
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063081182P | 2020-09-21 | 2020-09-21 | |
| PCT/US2021/050590 WO2022060931A1 (en) | 2020-09-21 | 2021-09-16 | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL301350A true IL301350A (en) | 2023-05-01 |
Family
ID=78087569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL301350A IL301350A (en) | 2020-09-21 | 2021-09-16 | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230348579A1 (https=) |
| EP (1) | EP4213940A1 (https=) |
| JP (1) | JP2023542521A (https=) |
| KR (1) | KR20230073261A (https=) |
| CN (1) | CN116261569A (https=) |
| AU (1) | AU2021344411A1 (https=) |
| CA (1) | CA3173003A1 (https=) |
| IL (1) | IL301350A (https=) |
| MX (1) | MX2023003256A (https=) |
| WO (1) | WO2022060931A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025166118A1 (en) | 2024-02-02 | 2025-08-07 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
-
2021
- 2021-09-16 EP EP21790712.0A patent/EP4213940A1/en active Pending
- 2021-09-16 MX MX2023003256A patent/MX2023003256A/es unknown
- 2021-09-16 IL IL301350A patent/IL301350A/en unknown
- 2021-09-16 AU AU2021344411A patent/AU2021344411A1/en active Pending
- 2021-09-16 KR KR1020237012983A patent/KR20230073261A/ko active Pending
- 2021-09-16 WO PCT/US2021/050590 patent/WO2022060931A1/en not_active Ceased
- 2021-09-16 CA CA3173003A patent/CA3173003A1/en active Pending
- 2021-09-16 JP JP2023518165A patent/JP2023542521A/ja active Pending
- 2021-09-16 CN CN202180065892.1A patent/CN116261569A/zh active Pending
- 2021-09-16 US US18/026,698 patent/US20230348579A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023542521A (ja) | 2023-10-10 |
| CN116261569A (zh) | 2023-06-13 |
| EP4213940A1 (en) | 2023-07-26 |
| AU2021344411A9 (en) | 2024-09-26 |
| AU2021344411A1 (en) | 2023-04-27 |
| KR20230073261A (ko) | 2023-05-25 |
| MX2023003256A (es) | 2023-04-11 |
| WO2022060931A1 (en) | 2022-03-24 |
| US20230348579A1 (en) | 2023-11-02 |
| CA3173003A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12460012B2 (en) | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients | |
| AU2024266818B2 (en) | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) | |
| US12404320B2 (en) | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients | |
| US20230235035A1 (en) | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients | |
| JP2026026191A (ja) | 造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を処置するための抗ｃ５抗体の用量及び投与 | |
| US20240018220A1 (en) | Methods of treating patients having complement disorders using anti-c5 antibodies | |
| KR20230134533A (ko) | 항-c5 항체를 이용한 보체 매개 혈전성 미세혈관병증의치료 방법 | |
| US20230348579A1 (en) | Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan) | |
| WO2022265915A1 (en) | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) | |
| US20240279320A1 (en) | Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm) | |
| TW202545563A (zh) | 用於治療iga腎病(igan)之抗c5抗體的劑量與投予 | |
| RU2822664C2 (ru) | ДОЗЫ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ АТИПИЧНОГО ГЕМОЛИТИКО-УРЕМИЧЕСКОГО СИНДРОМА (аГУС) | |
| US20210324066A1 (en) | Methods and Treatment Involving Excess Free Light |